Peptide Knowledge Base · Longevity

DSIP (Emideltide): what it is, what the evidence says, and its real status

A sleep-associated peptide with an evocative name and a thin, dated evidence base.

Can you actually get it?

Plain-English verdict: Education only.

Regulatory status: PCAC declined · not on Bulks List path.

How does DSIP (Emideltide) work?

A nine-amino-acid peptide first isolated in studies of sleep regulation; mechanism in humans is poorly characterized.

What it does — and what it does not do

What it does: Studied, mostly in older work, for sleep and stress-resilience interest.

What it does not do: It is not a proven sleep medication.

How honest is the evidence?

Evidence grade D — Animal and lab evidence; human trials still to come.

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Modern controlled human evidence is scarce; effect on sleep architecture is unconfirmed.

WADA status: Not prohibited.

How it is taken

No established human clinical dosing; research-stage.

Who should not take it

Not characterized in humans; not a substitute for evaluation of a sleep disorder.

Sources

Older DSIP sleep-regulation literature (limited modern replication) · FDA PCAC docket, Jul 2026

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 16, 2026 · Peptós.LIFE · Not medical advice.